How much funding has BioLattice raised?

BioLattice has raised $1.8M in total funding, most recently a Pre-Seed round.

When was BioLattice founded?

BioLattice was founded in 2014.

Where is BioLattice headquartered?

BioLattice is headquartered in Philadelphia, Pennsylvania, United States.

What industry is BioLattice in?

BioLattice operates in Biotech, Medtech, Healthcare.

BioLattice

Revolutionizing Cornea Repair

Philadelphia, United States · Founded 2014 · $1.8M raised

Biotech

Medtech

Healthcare

Headquarters: Philadelphia, Pennsylvania
Employees: 1–10
Founded: 2014
Business Model: B2B

Website: biolatticetech.com
Total Funding: $1.8M
Last Round: $1.8M Pre-SeedOct 2024
Rounds: 1

About

BioLattice Ophthalmics is an award-winning tissue engineering company founded by Amelia Zellander, PhD (tissue engineer and pharmaceutical scientist) and Linda Alunkal, MBA. The company is developing CorneaClear, a synthetic corneal implant designed as a true alternative to donor corneas. With 2 million people suffering from corneal blindness annually and only 1 in 70 patients obtaining donor tissue, BioLattice's engineered cornea also offers corrective vision capabilities. The company has received funding from Life Sciences Greenhouse Investments (LSGI) and won multiple pitch competitions including HiveBio's Silicon Valley competition ($20K) and the Startup of the Year award. Based in Philadelphia and backed by federal grants before transitioning to VC funding.

Summary

BioLattice is a Biotech company based in Philadelphia, United States, founded in 2014. It has raised $1.8M in total across 1 round, most recently a $1.8M Pre-Seed round in Oct 2024.